REduction of THRomboembolic EVents during Ablation using the laserballoon: The RETHREVA registry.
Martin EichenlaubArne PfeuferLars BehrensVolker KlaussMichael RoettingerTurgut BrodherrThorsten LewalterPublished in: Journal of cardiovascular electrophysiology (2018)
These data support the use of intravenous aspirin including monitoring of aspirin resistance in addition to ACT-guided heparin. An optimized protocol of heparin before TP, double TP, and intravenous aspirin in non-ARP resulted in a significantly lowered CE incidence and severity.
Keyphrases
- low dose
- high dose
- cardiovascular events
- antiplatelet therapy
- venous thromboembolism
- growth factor
- anti inflammatory drugs
- randomized controlled trial
- risk factors
- acute coronary syndrome
- electronic health record
- percutaneous coronary intervention
- cardiovascular disease
- atrial fibrillation
- big data
- radiofrequency ablation
- machine learning